EGTX.ST STO
Egetis Therapeutics AB (publ)
1W: +16.5%
1M: +17.1%
3M: +55.6%
YTD: +77.6%
1Y: +74.5%
3Y: +121.7%
5Y: +70.6%
kr 9.18 ($0.91)
-0.26 (-2.75%)
Weekly Expected Move ±9.5%
kr 7
kr 8
kr 9
kr 10
kr 11
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$62M
+35.4% ▲
5Y CAGR: +8.9%
Gross Profit
$12M
-64.1% ▼
Operating Income
-$347M
-5.3% ▼
Net Income
-$342M
+0.3% ▲
EPS (Diluted)
$-0.93
+17.0% ▲
EBITDA
-$347M
-9.3% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $38M | $22M | $58M | $46M | $62M |
| YoY Growth | -5.9% | -41.2% | +156.0% | -20.0% | +35.4% |
| Cost of Revenue | $97M | $143M | $204M | $12M | $50M |
| Gross Profit | -$58M | -$120M | -$147M | $34M | $12M |
| Gross Margin | -152.4% | -533.8% | -255.0% | 74.8% | 19.9% |
| R&D Expenses | $89M | $136M | $0 | $146M | $158M |
| SG&A Expenses | $15M | $74M | $173M | $215M | $201M |
| Operating Expenses | $47M | $55M | $178M | $364M | $359M |
| Operating Income | -$106M | -$198M | -$325M | -$329M | -$347M |
| Operating Margin | -276.3% | -880.4% | -563.9% | -714.5% | -555.9% |
| Interest Expense | $200K | $100K | $4M | $26M | $23M |
| Income Before Tax | -$105M | -$194M | -$327M | -$343M | -$342M |
| Tax Expense | $188K | -$4M | $100K | $300K | $400K |
| Net Income | -$105M | -$190M | -$327M | -$344M | -$342M |
| Net Margin | -273.9% | -842.2% | -567.5% | -745.3% | -548.9% |
| EPS (Diluted) | $-0.58 | $-0.98 | $-1.26 | $-1.12 | $-0.93 |
| EBITDA | -$102M | -$191M | -$319M | -$317M | -$347M |
| Shares Outstanding | 180M | 194M | 260M | 307M | 368M |